# An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

Study · id `cardio:ct-nct05013008` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05013008](<https://clinicaltrials.gov/study/NCT05013008>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05013008

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 951 participants.

## Technical summary

Registry record NCT05013008. Randomized; no masking; primary purpose other. Start 2021-08-18 (actual); primary completion 2021-12-31 (actual). Results posted on 2023-03-31.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 2
- Enrolled: 951 participants (enrolled count; ClinicalTrials.gov record NCT05013008, source copy `cardio:ctgov-nct05013008-2023-09-15`, retrieved 2026-10-26)
- Started: 2021-08-18 (actual) (ClinicalTrials.gov record NCT05013008, source copy `cardio:ctgov-nct05013008-2023-09-15`, retrieved 2026-10-26)
- Primary completion: 2021-12-31 (actual) (ClinicalTrials.gov record NCT05013008, source copy `cardio:ctgov-nct05013008-2023-09-15`, retrieved 2026-10-26)
- Completion: 2021-12-31 (actual) (ClinicalTrials.gov record NCT05013008, source copy `cardio:ctgov-nct05013008-2023-09-15`, retrieved 2026-10-26)
- Results first posted: 2023-03-31 (ClinicalTrials.gov record NCT05013008, source copy `cardio:ctgov-nct05013008-2023-09-15`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Belgium; Bulgaria; Canada; Czechia; Denmark; Finland; Hong Kong SAR China; Israel; Italy; Japan; Netherlands; Portugal; Russia; Singapore; South Korea; Spain; Sweden; Taiwan (ClinicalTrials.gov record NCT05013008, source copy `cardio:ctgov-nct05013008-2023-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05013008-2023-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
- Acronym: FIGARO-BM
- Condition: Chronic Kidney Disease
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Finerenone (Kerendia, BAY94-8862)
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 474a8c3ffe032ff53bfe7f834fb41360ab42ced74e730c2080164cf1b53799fd
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
